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Nicotinamide riboside or IL-17A signaling blockers to prevent 
liver disorders
Ana Teijeiro and Nabil Djouder
Hepatocelular Carcinoma (HCC) is the fifth most 
common cancer and one of the most frequent aggressive 
liver neoplasms [1-3]. HCC has a poor prognosis 
and treatments are not very effective. Overall liver 
transplantation remains the best option for patients with 
HCC. Unfortunately, important limitations mainly due 
to scarcity of good-quality donor organs, high costs and 
immunosuppression problems restrict liver transplantation. 
Therefore, alternative treatments are considered to delay 
HCC recurrence, including resection, radiofrequency 
ablation and, chemotherapy with sorafenib, which can 
extend the patient lifespan of 2-3 months maximum. When 
recurrence occurs aggressive surgical treatment may have 
the best possible outcome [1].
The main risk factors for HCC enclose infection of 
hepatitis B and C viruses (HBV and HCV, respectively), 
toxin poisoning, chronic alcohol consumption and 
hypernutrition-associated obesity [3]. Nutrient overload 
leads to nonalcoholic fatty liver disease (NAFLD), 
characterized by fat accumulation in the liver or steatosis 
and considered as an important liver disorder arising in 
the obese population or in patients with type 2 diabetes 
(T2D) or hyperlipidemia [3]. Hepatic steatosis combined 
with low-grade inflammation and liver injury, triggers 
the development of nonalcoholic steatohepatitis (NASH) 
which can transit to HCC [3]. Thus, high body mass index 
increases HCC risks and overall cancer-related death 
[3]. Since obesity is reaching epidemic proportions, the 
absolute burden of NASH-related HCC is even higher 
than that of HCV/HBV-related HCC, therefore reaching 
a dramatic and alarming situation worldwide without any 
effective treatment.
NASH is often accompanied by several metabolic 
disorders including the metabolic syndrome comprising 
T2D [3]. Nutrient overload, through high insulin levels, 
deregulates hepatic functions, affecting the whole 
body metabolic balance leading to severe hepatic 
disorders. Nutrients can be inflammatory orchestrating 
NASH and HCC development [3]. We have recently 
demonstrated how nutrient excess causes immune 
responses and metabolic dysfunctions triggering hepatic 
fat accumulation, ultimately leading to NASH and HCC. 
In this regard, we have generated a genetically 
engineered mouse model, hURI-tetOFFhep mouse, in 
which, unconventional prefoldin RPB5 interactor (URI) 
is specifically expressed in murine hepatocytes inducing 
NASH and spontaneous HCC during a multistep process 
[2, 3]. Importantly, hepatic URI levels increase upon 
inflammatory cues, HBV infection or nutrient overload 
and thus, orchestrate NASH and NASH-induced HCC. 
HCC in hURI-tetOFFhep mice covers HBV-associated 
human HCC signature [2, 3]. Unlike other models of 
NASH, such as methionine and choline deficient diet 
(MCD) or high fat diet (HFD) in which HCCs are not 
detected or, appearance is at very low incidence (about 
4%), hURI-tetOFFhep mouse recapitulates many features 
of human HCC and thus, represents an excellent model to 
study NASH and its progression to HCC. hURI-tetOFFhep 
mouse also develops T2D-like phenotype, rendering this 
model very attractive to elucidate mechanisms of hepatic 
metabolic dysfunctions, NASH and HCC [3]. Recently, 
another mouse model recapitulating key features of human 
metabolic syndrome, NASH, and HCC was developed by 
long-term feeding of a choline-deficient HFD (CD-HFD) 
[4], representing an alternative elegant model of NASH-
induced HCC.
hURI-tetOFFhep mouse reveals histopathological 
features of human NASH including the presence of 
Mallory-Denk bodies, moderate steatosis, ballooned 
hepatocytes, immune cell infiltration, and liver injury 
[3]. Interestingly, hepatic URI expression is modulated 
by nutrient surpluses. Increased URI in hepatocytes 
inhibits aryl hydrocarbon (AhR) and estrogen receptor 
(ER). AhR and ER modulate L-tryptophan/kynurenine/
nicotinamide adenine dinucleotide (NAD+) metabolism 
and, their inhibition by URI decreases NAD+ levels in 
hepatocytes, thereby inducing DNA damage and initiating 
hepatic disorders. Thus, hURI-tetOFFhep mouse mimics 
the nutrient overload model, both representing genotoxic 
stress models. Nicotinamide riboside (NR) a pyridine-
nucleoside form of vitamin B3 and precursor to NAD+ 
abolishes DNA damage in hURI-tetOFFhep and in HFD-
fed mice [1-3]. Boosting NAD+ concentrations can also 
be therapeutic in certain metabolic disorders, such as T2D 
[5, 6] and fatty liver disease [7] and, potentially protects 
against obesity [8]. Importantly, boosting NAD+ by NR 
prevents HCC [1, 2]. Thus, NR may represent a preventive 
treatment for metabolic dysfunctions such as T2D, NASH 
and HCC.
DNA damage precedes hepatic inflammation and 
is essential to trigger T helper 17 (Th17) cells to the 
liver since NR treatment prevents T cell recruitment 
Editorial
2www.impactjournals.com/oncoscience Oncoscience
to livers of  hURI-tetOFFhep and HFD-treated mice [3]. 
Tryptophan is reported to promote Th17 differentiation in 
vitro. Hence, inhibition of kynurenine pathway possibly 
increases tryptophan concentrations supporting Th17 
differentiation in the hURI-tetOFFhep model. Secretion of 
IL-17A by Th17 cells generates systemic inflammation 
and promotes neutrophil recruitment to the white adipose 
tissue (WAT) thereby, leading to insulin resistance (IR) 
and lipolysis. Released free fatty acids are taken-up by the 
liver and stored as triglycerides in hepatocytes, leading to 
steatosis, liver injury and NASH. Inflammation precedes 
IR, steatosis and liver injury and, suggests that several 
hits are needed for NASH development, supporting the 
multi-hit hypothesis [3]. Several other studies suggest 
that inflammation is the driving force in NASH [3] and 
therefore, as demonstrated in the hURI-tetOFFhep model, 
inflammation is determinant for the disease development. 
Steatosis per se may not account for the long-term 
prognosis of NASH.
Furthermore, IR seems to precede steatosis and 
NASH development suggesting that T2D is not a 
consequence of hepatic fat accumulation but T2D patients 
may progress to NASH and HCC. Abolishing genotoxicity 
with NR or blocking IL-17A signaling by anti-IL-17A 
antibodies or digoxin treatment (blocking Th17 cell 
differentiation) may provide an inexpensive, accessible 
and immediately translatable therapy for NASH and HCC, 
particularly in diabetic patients or individuals exposed at 
high risks.
In conclusion, our data identify mechanisms linking 
nutrient surpluses, inflammation, IR, NASH and HCC 
and, define genotoxic stress and IL-17A as the initiating 
and promoting players, respectively, in hepatic metabolic 
dysfunctions transiting to HCC [3]. These findings open 
doors to personalized medicine to prevent and cure NASH 
and NASH-induced HCC. We propose that patients at 
high risk of developing NASH (e.g. obese, T2D or HCV-
infected patients) can be treated with NR, anti-IL-17A 
antibodies or digoxin preventing IR, steatosis, NASH and/
or HCC development (Figure). 
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Figure 1. NR or IL-17A blockers against NASH-induced HCC development. Inflammatory cues or nutrient overload causes increased 
hepatic URI which, triggers DNA damage and orchestrates systemic inflammation-associated IL-17A ultimately inducing insulin resistance, 
hepatic lipid accumulation and NASH progressing to HCC.
